The Influence of American Medical Reform on Chinese Pharmaceutical Industry

Since there is no essential difference between the Senate and the House Medical Reform Act, both Democrats and Republicans agree that the current U.S. health system needs to be reformed. The possibility of a compromised medical reform plan is quite significant within this year. Of course, this reform will not change the basic pattern of the US pharmaceutical market, nor will it have a fundamental impact on the US pharmaceutical industry.

The U.S. pharmaceutical market is the largest pharmaceutical market in the world. Under the background of U.S. medical reform, if Chinese pharmaceutical companies can successfully enter this huge market, it is certainly the most ideal situation. However, Chinese pharmaceutical companies are still faced with difficulties in entering the U.S. market; The import of drugs, especially prescription drugs, because it will seriously affect the profits of the US pharmaceutical industry. Through out-of-hospital lobbying activities, the pharmaceutical industry has the ability to influence and even influence the formulation and introduction of US policies and regulations;

The reasons why the United States opposes the entry of foreign drugs into the U.S. market include: 1) If the import of prescription drugs is opened, the profits of U.S. pharmaceutical companies will be reduced, resulting in lower investment in research and development. This will inevitably affect the launch of new effective drugs in the future; 2) If open to the outside world In the pharmaceutical market, the U.S. pharmaceutical industry will experience further declines in efficiency, and more layoffs may come; 3) The medical cost savings from importing cheap drugs may not be sufficient to make up for the increased quality of regulatory inputs. Imported drugs may be economically Not worth the candle;

Given the poor quality and safety records of Chinese food and drug products in the past, the quality issue will become an important obstacle to China's related products entering the US market. Those affected by China's drug reputation will include those that produce safe and effective drugs.

In addition to the restrictions imposed by the US regulatory authorities on foreign drug imports and the protection of the U.S. pharmaceutical industry for the domestic market, the relatively low competitiveness of Chinese pharmaceutical companies and the lack of competitive products are also important factors that restrict the use of U.S. medical reform in the U.S. market. ;

While China's pharmaceutical industry has faced numerous barriers to entry into the US pharmaceutical market, a new round of expansion of multinational pharmaceutical giants in China has begun, which is a serious challenge for local companies.